Cargando…
Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2
Effective treatment or vaccine is not yet available for combating SARS coronavirus 2 (SARS-CoV-2) that caused the COVID-19 pandemic. Recent studies showed that two drugs, Camostat and Nafamostat, might be repurposed to treat COVID-19 by inhibiting human TMPRSS2 required for proteolytic activation of...
Autores principales: | Zhu, Haixia, Du, Wenhao, Song, Menghua, Liu, Qing, Herrmann, Andreas, Huang, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809394/ https://www.ncbi.nlm.nih.gov/pubmed/33505639 http://dx.doi.org/10.1016/j.csbj.2020.12.035 |
Ejemplares similares
-
Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat
por: Sun, Gaohui, et al.
Publicado: (2021) -
Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors
por: C, Amrutha M, et al.
Publicado: (2023) -
Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat
por: Hempel, Tim, et al.
Publicado: (2020) -
Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations
por: Ramakrishnan, Jaganathan, et al.
Publicado: (2021) -
Camostat Does Not Inhibit the Proteolytic Activity of Neutrophil Serine Proteases
por: Assylbekova, Akmaral, et al.
Publicado: (2022)